Tumanggong, Raisa .
HRN: 20-14-81 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/19/2024
CO-AMOXICLAV 625MG (TAB)
09/19/2024
09/26/2024
ORAL
625mg
BID
S/P NSD With RMLE
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes